STAT+: Biden changes will force health insurers to speed up and get more specific if they want to deny care
The Biden administration moved Wednesday to force insurance companies to give specific reasons for denying…
Category: Politics
.jpg)
STAT+: Copay coupons for some drugs must count toward deductibles, after Biden court move
WASHINGTON — Insurers will have to count drug copay coupons toward deductibles and patient spending…
The big any-day-now biotech news we’re keeping an eye on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The state of Medicare Advantage, in one chart
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
Health care negotiations on Capitol Hill are clear as mud
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
The four biotech stories you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The new NIH director is walking a tightrope on Biden’s drug pricing vision
WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally…
STAT+: Could private equity be the future of private practice? A new lobbying group thinks so
Private equity gets a bad rap in health care. But some doctors see that kind…
Novartis reportedly decides to pass on Cytokinetics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Courts will decide the future of Medicare’s power to negotiate drug prices within months
WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare…
JPM Day 3 had a cautiously optimistic outlook
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
After grilling Fauci on Covid origins, House Republicans want to consider new rules for foreign research
WASHINGTON — House Republicans want to explore tighter inspection and safety requirements for infectious disease…
Advocates expect Supreme Court Idaho abortion decision to fuel efforts to further restrict access
The U.S. Supreme Court’s decision to consider the legality of Idaho’s abortion law — and…
Anthony Fauci talked Covid in Congress in a nine-hour, closed-door grilling — and that was just day one
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: HHS’s Xavier Becerra, once an ‘invisible’ secretary, is racing to cement a clearer legacy
WASHINGTON — He’s been called the “invisible” secretary. So far removed from the White House…
Opinion: Sen. Maggie Hassan on what Congress must do next to fight the opioid crisis
Few public health challenges have been more daunting and persistent than the opioid crisis, which…
STAT+: HHS names inaugural chief competition officer
The Department of Health and Human Services will name Stacy Sanders as its new chief…
Biden’s FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit?
WASHINGTON — The Biden administration has approved Florida Gov. Ron DeSantis’ plan to import a…
STAT+: Another major pharma company departs BIO
WASHINGTON — UCB left BIO at the end of 2023, the second major member company to…
Why CG Oncology will be the first test of 2024’s IPO waters
Want to stay on top of the science and politics driving biotech today? Sign up to get…
An ugly fight over care for the poor in Texas
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: 3 health policies states are taking on in 2024
For most states, the new year means a new legislative session. STAT’s taking a look…
STAT+: 3 FDA staffers to watch in 2024
WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024…
.jpg)
STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation
WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s…
The clock is ticking, and cytokinetics is running out of December
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?
WASHINGTON — Sometime next year drug and medical device companies will have to tell the…
What the new health counsels at FTC, DOJ, and HHS might do
Three major government agencies are adding new officials to investigate price-gouging in health care —…
Opinion: The Biden administration’s plan to use march-in rights to address drug prices would kill future world-changing innovations
The Bayh-Dole Act is widely credited with kickstarting a new era of American innovation involving the…
FDA chastens pet companies over antibiotics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sanders blames food companies for diabetes epidemic
WASHINGTON — Sen. Bernie Sanders (I-Vt.) has a new corporate target: the food industry. Sanders…
STAT+: Why FDA product recalls have spiked in recent years
Either American products are getting worse, or scrutiny over their safety is getting tougher. Whichever…
Is it time to worry about Moderna?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Supreme court will decide abortion pill access
WASHINGTON — The Supreme Court agreed Wednesday to take on whether Americans can access a…
House passes site-neutral policy, transparency, PBM reform package
WASHINGTON — The House passed a relatively major health care package late Monday, an end-of-year…
STAT+: UnitedHealth executive to head health insurance group AHIP
WASHINGTON — An executive at insurance giant UnitedHealth Group is slated to be the next…
STAT+: Hot antitrust environment hangs over called-off merger between Cigna and Humana
Less than two weeks after reports surfaced saying Cigna and Humana were considering combining into…
The biotech news you missed from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
CRISPR is about to make history. Here’s the 5-minute rundown of what to expect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Senate committee launches bipartisan investigation into private equity ownership of hospitals
The two leaders of the Senate Budget Committee on Thursday launched a bipartisan investigation into…
Diabetes ‘epidemic’ gets a Senate hearing
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT Health News: Abortion ‘companion networks,’ NEJM’s racist past, and other stories you need to read
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Eli Lilly’s latest $1.4 billion deal might come unglued
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: To lower drug prices, White House takes new aim at pharma patents
WASHINGTON — The White House is throwing its support behind a controversial authority that allows…
STAT+: Pfizer plans to depart BIO
WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources…
STAT+: Senate panel considers Medicare policy fixes to drug shortages
WASHINGTON — Members of the Senate Finance Committee took their first steps today toward using…
STAT Morning Rounds: The health news you need to read today
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Carmot’s chance of beating the odds in the biotech market just ended
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John…
STAT+: Cancer drug shortages won’t get better under Biden’s latest plan
WASHINGTON — President Biden’s new plan to curb drug shortages by boosting domestic drug production…
STAT+: Official: FDA needs staff influx to meet gene therapy needs
WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its…